Loading...
  • secretion
  • Y. Chowers, L. Cahalon, M. Lahav, H. Schor, R. Tal, S. Bar-Meir, and M. Lévite, Somatostatin through its specific receptor inhibits spontaneous and TNF-_- and bacteria-induced IL-8 and IL-1 secretion from intestinal epithelial cells. (springer.com)
  • somatostatin
  • M.E. Mato, M. Puig-Domingo, O. Fornas, and S.M. Webb, Expression of the somatostatin gene and receptors in the rat harderian gland. (springer.com)
  • A. Schonbrunn and A.H. Tashjian Jr., Characterization of functional receptors for somatostatin in rat pituitary cells in culture. (springer.com)
  • liraglutide
  • Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study," The Lancet , vol. 381, no. 9861, pp. 117-124, 2013. (hindawi.com)
  • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)," The Lancet , vol. 374, no. 9683, pp. 39-47, 2009. (hindawi.com)
  • Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme," Diabetes, Obesity and Metabolism , vol. 15, no. 1, pp. 42-54, 2013. (hindawi.com)
  • Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)," Diabetic Medicine , vol. 26, no. 3, pp. 268-278, 2009. (hindawi.com)
  • Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)," Diabetes Care , vol. 32, no. 7, pp. 1224-1230, 2009. (hindawi.com)
  • This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone. (diabetesjournals.org)
  • HealthDay News) - For patients with type 2 diabetes and high cardiovascular risk receiving usual care, the addition of liraglutide is associated with lower rates of development and progression of diabetic kidney disease, according to a study published in the Aug. 31 issue of the New England Journal of Medicine . (empr.com)
  • Johannes F.E. Mann, M.D., from the Friedrich Alexander University of Erlangen in Germany, and colleagues reported the prespecified renal outcomes of a randomized controlled trial involving patients with type 2 diabetes receiving usual care who were assigned to liraglutide or placebo. (empr.com)
  • incretin
  • The observation that mice with homozygous disruption of the GLP-1 receptor gene are diabetic with a diminished incretin response to glucose underlines the first function in vivo. (diabetesjournals.org)
  • He also reviews the current American Diabetes Association and American Association of Clinical Endocrinologists treatment guidelines and shows where the incretin agents fall within these regimens. (jaoa.org)
  • concentrations
  • Padidela R, Patterson M, Sharief N, Ghatei M, Hussain K. Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period. (springer.com)
  • inhibitors
  • Already, the diabetes field has witnessed the impact of therapeutic GLP-1 mimetics and dipeptidyl peptidase (DPP)4 inhibitors, which, respectively, mimic endogenous active GLP-1 and slow its enzymatic degradation in the circulation ( 2 ). (diabetesjournals.org)
  • clinical
  • 1 ) summarize the outcomes of the phase 2a and phase 2b clinical trials of LY2409021, a small-molecule glucagon receptor antagonist (GRA). (diabetesjournals.org)
  • Here, we place their success in perspective and discuss the advantages and concerns relating to glucagon-based therapeutics as this line of drugs comes closer than ever to achieving their clinical potential. (diabetesjournals.org)
  • Furthermore, this previous study did not evaluate the effect of intermittent GLP-1 receptor stimulation, which is of substantial clinical relevance. (diabetesjournals.org)
  • Thank you for your interest in spreading the word about Clinical Diabetes. (diabetesjournals.org)
  • Message Body (Your Name) thought you would like to see this page from the Clinical Diabetes web site. (diabetesjournals.org)
  • With this course you will get updated on cutting-edge diabetes and obesity research including biological, genetic and clinical aspects as well as prevention and epidemiology of diabetes and obesity. (coursera.org)
  • T2DM
  • A patient-centered approach to the treatment of T2DM is advised [ 8 , 9 , 10 ], with the choice of diabetes therapy being based on attributes specific to both patients and the medication. (springer.com)
  • therapeutics
  • Additionally, the report provides an overview of key players involved in Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development and features dormant and discontinued projects. (acutemarketreports.com)
  • Heptares Therapeutics, the leading GPCR drug discovery and development company, announces the publication of a scientific article describing the high resolution X-ray crystal structure of the corticotropin-releasing factor receptor 1 (CRF1) receptor. (prnewswire.com)
  • Patients
  • The observed correlation between elevated postprandial GLP-1 levels and improved glucose homeostasis in patients after bariatric surgery indicates that the body has excess capacity in the GLP-1 axis that can be recruited in obese diabetic patients, with downstream beneficial effects on food intake and diabetes control ( 4 ). (diabetesjournals.org)
  • Bariatric surgeries, including vertical sleeve gastrectomy (VSG), resolve diabetes in 40-50% of patients. (highwire.org)
  • Expression
  • Quantitative PCR revealed enriched expression of the SCFA receptors ffar2 ( grp43) and ffar3 (gpr41) in GLP-1-secreting L cells, and consistent with the reported coupling of GPR43 to Gq signaling pathways, SCFAs raised cytosolic Ca 2+ in L cells in primary culture. (diabetesjournals.org)
  • treatment
  • These results highlight SCFAs and their receptors as potential targets for the treatment of diabetes. (diabetesjournals.org)
  • Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. (prnewswire.com)
  • The role of incretins in glucose homeostasis and diabetes treatment. (springer.com)